Theresa Tse
Chairman at SINO BIOPHARMACEUTICAL LIMITED
Net worth: 2 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ping Tse | M | 72 |
Sino Biopharmaceutical (Beijing) Ltd.
Sino Biopharmaceutical (Beijing) Ltd. Miscellaneous Commercial ServicesCommercial Services Sino Biopharmaceutical (Beijing) Ltd. is an investment holding company. Its sole asset is its 33.6% interest in Beijing Tide Pharmaceutical Co., Ltd., a pharmaceutical company established in China with limited liability, which develops, manufactures, and market pharmaceutical products. Sino Biopharmaceutical (Beijing) was founded on December 31, 2007 and is headquartered in Hong Kong.
Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | 24 years |
Benjamin Toogood | M | 48 |
invoX Pharma Ltd.
invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The private company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | 3 years |
Hsin Tse | M | 54 |
Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | 29 years |
Philip Duong | M | 34 |
invoX Pharma Ltd.
invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The private company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | 4 years |
Viktor Drvota | M | 59 | 9 years | |
S Y Tse | M | 29 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | 5 years |
Theresa Tse | F | 32 |
invoX Pharma Ltd.
invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The private company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | - |
Per Gunnar Ernst Aniansson | M | 58 | 3 years | |
Zheng Fei Lu | M | 61 | 19 years | |
Da Kui Li | M | 80 | 20 years | |
Anna Lefevre Skjöldebrand | F | 55 | 3 years | |
Ming Qin Li | F | 66 | 27 years | |
Lu Fu Zhang | M | 67 | 9 years | |
Kwok Tung Li | M | 69 | 4 years | |
Elisabet Gimbringer | F | 59 | 9 years | |
Björn Cochlovius | M | 56 | 4 years | |
Hong Lu | F | 54 | 9 years | |
Kang Xin Yu | M | - |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | - |
Hong Jun Wei | M | - |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | - |
Ke Ying Liu | F | 59 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | - |
Qian Li | F | - | 15 years | |
Rui Wang | M | - |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | - |
Hans Christopher Toll | M | 56 | 2 years | |
Sean Chen | M | 46 | 2 years | |
Fai Chia | F | 66 |
Sino Biopharmaceutical (Beijing) Ltd.
Sino Biopharmaceutical (Beijing) Ltd. Miscellaneous Commercial ServicesCommercial Services Sino Biopharmaceutical (Beijing) Ltd. is an investment holding company. Its sole asset is its 33.6% interest in Beijing Tide Pharmaceutical Co., Ltd., a pharmaceutical company established in China with limited liability, which develops, manufactures, and market pharmaceutical products. Sino Biopharmaceutical (Beijing) was founded on December 31, 2007 and is headquartered in Hong Kong. | - |
Linda Spahiu | M | 39 | - | |
Johan Dighed | M | 51 | 4 years | |
John Öhd | M | 53 | 4 years | |
Zhao Hui Hu | M | 60 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | - |
Zhou Shan Tian | M | 60 | 27 years | |
Oi Nin Chan | M | 56 | 9 years | |
Eva Montgomerie | F | 66 | 17 years | |
Thomas Andersson | M | 72 | - | |
Bao Wen Zhang | M | 67 |
Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
| - |
Cheung Ling Cheng | F | 60 | 19 years | |
Chun Ling Li | F | 53 | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Hans Lennart Rudolf Wigzell | M | 86 | 14 years | |
Fredrik Järrsten | M | 57 | 4 years | |
Gunnar Magnus Modee Persson | M | 64 | 3 years | |
Karl Härfstrand | M | 66 | 2 years | |
Xiao Yang Xu | M | 61 | - | |
Ulf Göran Richenberg | M | 69 | 12 years | |
Yi Li | M | 63 | 2 years | |
Sau Fung Leung | F | - | - | |
Wei Nong Ye | M | 61 | 20 years | |
Richard Bethell | M | 61 | - | |
Shan Chun Wang | M | 56 | 7 years | |
Mao Li | M | 66 | - | |
Jia yin Ma | F | 47 | - | |
Li Mao | M | 67 | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Cayman Islands | 25 | 50.00% |
Sweden | 20 | 40.00% |
China | 9 | 18.00% |
United Kingdom | 3 | 6.00% |
Hong Kong | 2 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Theresa Tse
- Personal Network